Related references
Note: Only part of the references are listed.Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Julia Dietz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Julia Dietz et al.
JOURNAL OF HEPATOLOGY (2021)
Hepatitis C Virus Replication
Keisuke Tabata et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2020)
Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial
Robert S. Brown et al.
JOURNAL OF HEPATOLOGY (2020)
Systematic review and meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients
Achintya D. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors
Hayato Hikita et al.
SEMINARS IN LIVER DISEASE (2020)
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
Julia Dietz et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen
Adolfo de Salazar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions
Julia Dietz et al.
LIVER INTERNATIONAL (2020)
Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C
Steven Flamm et al.
JOURNAL OF HEPATOLOGY (2020)
Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir
David A Smith et al.
JOURNAL OF HEPATOLOGY (2020)
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment
Naveed Janjua et al.
JOURNAL OF HEPATOLOGY (2020)
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection
Shintaro Takaki et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2020)
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
David Wyles et al.
JOURNAL OF HEPATOLOGY (2019)
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
Brian Pearlman et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir
Peter A. C. Wing et al.
GASTROENTEROLOGY (2019)
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
Sanne Brun Jensen et al.
HEPATOLOGY (2019)
Analysis of long-term persistence of HCV resistance-associated substitutions within NS3, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure
Julia Dietz et al.
JOURNAL OF HEPATOLOGY (2019)
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients
Pamela S. Belperio et al.
JOURNAL OF VIRAL HEPATITIS (2019)
In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6
Hadas Dvory-Sobol et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Jordi Llaneras et al.
JOURNAL OF HEPATOLOGY (2019)
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M. Borgia et al.
JOURNAL OF HEPATOLOGY (2019)
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Ana Belen Perez et al.
JOURNAL OF HEPATOLOGY (2019)
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
Anna S. Lok et al.
GASTROENTEROLOGY (2019)
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C
Kate Childs et al.
JOURNAL OF HEPATOLOGY (2019)
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure
Elisabetta Degasperi et al.
JOURNAL OF HEPATOLOGY (2019)
Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naive subjects
Bin Han et al.
ANTIVIRAL RESEARCH (2019)
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Lai Wei et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Rafael Esteban et al.
GASTROENTEROLOGY (2018)
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Julia Dietz et al.
GASTROENTEROLOGY (2018)
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants
Judith M. Gottwein et al.
GASTROENTEROLOGY (2018)
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
Christophe Hezode et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
JOURNAL OF HEPATOLOGY (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Fabien Zoulim et al.
VIROLOGY JOURNAL (2018)
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection
Frederick Lahser et al.
ANTIVIRAL THERAPY (2018)
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2018)
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir
David Wyles et al.
ANTIVIRAL THERAPY (2018)
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A-or NS3-Containing Regimen: The ANRS HC34 REVENGE Study
Victor de Ledinghen et al.
CLINICAL INFECTIOUS DISEASES (2018)
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin
Fiona McPhee et al.
ANTIVIRAL THERAPY (2017)
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Paul Kwo et al.
GASTROENTEROLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
Tania M. Welzel et al.
JOURNAL OF HEPATOLOGY (2017)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
M. Bourliere et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network
Loreta A. Kondili et al.
PLOS ONE (2017)
Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
Tatsuo Kanda et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection
Ana Maria Ortega-Prieto et al.
VACCINES (2017)
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2016)
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Christoph Sarrazin
JOURNAL OF HEPATOLOGY (2016)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir
Simone Susser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
Christoph Sarrazin et al.
ANTIVIRAL RESEARCH (2015)
RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR- BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
M. P. Curry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
J. J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus-Infected Patients Following TMC435 Monotherapy
Oliver Lenz et al.
GASTROENTEROLOGY (2012)
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b
J. Vermehren et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
Simone Susser et al.
JOURNAL OF CLINICAL VIROLOGY (2011)
New kinetic models for the hepatitis C virus
AS Perelson et al.
HEPATOLOGY (2005)
Share Paper
